Latham Group Refinances Capital Structure with New Credit Facilities

Latham Group (SWIM) refinanced its capital structure with new credit facilities totaling $375 million. The facilities include a $75 million revolving credit line and a $300 million term loan, both secured by company assets. Proceeds were used to repay existing debt. The facilities mature in 2031 and 2033, respectively, and include leverage-based interest margins and covenants.

Original reporting
Published Aug 22, 2026, 1:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 23, 2026, 10:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Latham Group Refinances Capital Structure with New Credit Facilities — source image
Decision brief

The 30-second read

Med
01

Why it matters

The refinancing provides liquidity and extends debt maturities, potentially supporting operations but also increases leverage.

02

Market read

Primary corporate action that may affect Latham Group's stock price and sector sentiment.

03

What to watch

terms of leverage tests and covenant strictness may affect future borrowing capacity

Relevance 7/10Novelty 7/10Timing: recent refinancing disclosed Aug 20

Background

Latham Group announced a new senior secured credit agreement with a $75M revolving facility and a $300M term loan, repaying its prior 2022 credit facility.

Market effects

refinancing may improve liquidity for oilfield services sector

potential modest impact on Canadian energy services market

limited to investors with exposure to Latham Group

Counterpoint

refinancing could signal cash flow pressure despite added debt

Key entities

  • Latham Group

    Oilfield services provider executing the refinancing

Related articles

$FULCMedAI 8/10

Latham Advises Frazier Life Sciences on Private Placement Financing in Connection With Fulcrum Therapeutics and Slate Medicines Merger

Fulcrum Therapeutics (Nasdaq: FULC) and Slate Medicines announced a definitive all-stock merger. The combined company will operate as Slate Medicines, Inc. and is expected to trade on Nasdaq as SLTE. Slate secured commitments for an oversubscribed concurrent private placement of $245 million led by Frazier Life Sciences, with other healthcare investors participating.

$SWIMMedAI 8/10

Latham Group (SWIM) Q2 2026 Earnings Call Transcript

Latham Group, Inc. (SWIM) reported Q2 2026 net sales of $197.5 million, up 14.4% year over year, driven by 10.3% organic growth and the Freedom Pools acquisition. Adjusted EBITDA rose to $44.6 million. Net income fell to $12.8 million due to a $5.0 million FX impact. Full-year guidance: net sales $600 million to $620 million, adjusted EBITDA $110 million to $120 million.

$LOGCMedAI 8/10

Latham Represents Blackstone Credit & Insurance in Financing for ContextLogic’s Acquisition of gChem for US$850 Million

ContextLogic Holdings (OTCQB: LOGC) said it will acquire gChem, the holding company of Gaylord Chemical and subsidiaries, from funds managed by EagleTree Capital and co-investors. The deal values gChem at an enterprise value of US$850 million. Financing will come from Blackstone Credit & Insurance, including a US$250 million term loan and US$25 million revolver, per the company.